title: [Comparison of two initial mobilizing strategies of peripheral blood stem cells for autologous transplantation in patients with lymphoma and human immunodeficiency virus infection].
abstract: OBJECTIVE
  Several studies have demonstrated the feasibility of autologous stem cell transplantation (ASCT) in patients with lymphoma and human immunodeficiency virus (HIV) infection. HIV infection has been described as a risk factor for poor mobilization. The aim of this study was to compare the results of two mobilization strategies of peripheral blood stem cells (PBSC) in patients with lymphoma and HIV infection in seven Spanish hospitals.
  
  
  METHODS
  The following variables were collected: demographic, clinical and biological features, previous chemotherapies and outcomes, as well as mobilization's strategies (classified in two groups: 1) G-CSF, and 2) G-CSF + chemotherapy).
  
  
  RESULTS
  Between January 2000 and May 2010, 42 patients with lymphoma and HIV infection were referred for ASCT. The rate of successful mobilization (collection >1.60 × 10(6) CD34 cells/kg) with the first regimen was 67%, with no differences between those patients mobilized with G-CSF or with G-CSF + chemotherapy (16 [72%] and 12 [60%], respectively; p=0.382). The status of the lymphoma at the time of mobilization was the only factor for successful mobilization (20/22 patients [91%] in complete remission [CR] mobilized adequately versus 5/12 [58%] in partial remission [PR]; p=0.038).
  
  
  CONCLUSIONS
  In patients with lymphoma and HIV infection, mobilization with G-CSF was as effective as mobilization with chemotherapy followed by G-CSF. The stage of disease prior to the mobilization was the main risk factor for the success of mobilization, with better results in patients mobilized in remission of the lymphoma.
authors.affiliation: ICO-Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Institut de Recerca contra la Leucèmia Josep Carreras, Badalona, Barcelona, Spain.
authors.forename: Miguel
authors.initials: M
authors.lastname: Sagüés
authors.forename: Juan-Manuel
authors.initials: JM
authors.lastname: Sancho
authors.forename: David
authors.initials: D
authors.lastname: Serrano
authors.forename: Pascual
authors.initials: P
authors.lastname: Balsalobre
authors.forename: Jorge
authors.initials: J
authors.lastname: Gayoso
authors.forename: Mireia
authors.initials: M
authors.lastname: Morgades
authors.forename: Eulogio
authors.initials: E
authors.lastname: Conde
authors.forename: Arturo
authors.initials: A
authors.lastname: Iriondo
authors.forename: Rosario
authors.initials: R
authors.lastname: Varela
authors.forename: Lourdes
authors.initials: L
authors.lastname: Escoda
authors.forename: Blanca
authors.initials: B
authors.lastname: Xicoy
authors.forename: Ildefonso
authors.initials: I
authors.lastname: Espigado
authors.forename: Pascual
authors.initials: P
authors.lastname: Fernández-Abellán
authors.forename: Jose-Luis
authors.initials: JL
authors.lastname: Díez
authors.forename: Josep-María
authors.initials: JM
authors.lastname: Ribera
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D016015:Logistic Models; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D036102:Peripheral Blood Stem Cell Transplantation; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor